Division of Nephrology, Department of Medicine, Suleyman Demirel University School of Medicine, Isparta, Turkey.
Nephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
Drugs. 2018 Jul;78(11):1073-1083. doi: 10.1007/s40265-018-0942-2.
Interleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.
白细胞介素 (IL)-1α 和 IL-1β 是促炎细胞因子，在许多疾病中发挥作用，如类风湿关节炎、幼年特发性关节炎、痛风和周期性炎症综合征，包括家族性地中海热和穆-韦二氏综合征。靶向 IL-1 的药物，如重组 IL-1Ra（anakinra）、中和抗 IL-1β 抗体（canakinumab）和 IL-1β 陷阱（rilonacept），已用于临床治疗这些疾病。此外，实验证据表明 IL-1 在肾脏疾病和高血压中的作用，靶向 IL-1 在高心血管风险患者、血液透析和肾移植患者中显示出有前景的结果。我们现在总结了靶向 IL-1 在肾脏疾病患者中的潜在作用的相关知识。
